leisure time -WSS

leisure time

author：hotspot 2025-09-27 12:58:20 - browse：768

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： The Pandemic Treaty must support building strong health systems

WSS

R1 RCM gets $5.8 billion buyout offer from private equity firm

Change Healthcare can notify patients about the breach, HHS says

Alabama IVF ruling threatens families facing fatal genetic disease

HIV drugs protect against transmission, even in unprotected sex

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ASCO: Palliative care found as helpful given virtually as in person

focus

leisure time

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Moonlake's readout produced a cash windfall. Risks remain

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

How to save PrEP access — and even expand it

Obesity drugs seen as possible treatment for liver disease MASH

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

entertainment

HIV drugs protect against transmission, even in unprotected sex

NIH study of ME/CFS points to clear biological hallmarks

Innovation in antibiotics is ailing. 'Brain drain' may kill it

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

leisure time

focus

hotspot

hotspot